Item 5.02 Departure of Directors or Certain Officers; Election of Directors;


          Appointment of Certain Officers; Compensatory Arrangements of Certain
          Officers.

On August 1, 2022 (the "Grant Date"), the Compensation Committee of the Board of Directors of Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the "Company"), approved a grant of stock options to Dr. Matthew Angel (the "Options") to purchase up to 2,487,003 shares of the Company's common stock, par value $0.005 per share, at an exercise price of $0.49 per share, which was the closing price of the common stock on the trading day immediately preceding the Grant Date. The Committee granted the Options in connection with Dr. Angel's service as the Company's Interim Chief Executive Officer and President. Two forty-eighths (2/48) of the Options vested on the Grant Date, with the remaining Options vesting in substantially equal monthly installments over the subsequent forty-six months, subject to Dr. Angel's continued employment with the Company. The Options expire on August 1, 2032.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses